Selected data models

You must log in to select data models for download or further analysis.

15 Search results.
Relevance Rating New first Old first

E2906 Abbreviated Comprehensive Geriatric Assessment Battery NCT01041703

- 9/20/21 - 1 form, 13 itemgroups, 64 items, 1 language
Itemgroups: Header Module, On Treatment Report Period, Data amendment, Assessment Date, Mini Mental Examination Section, GDS, ADL, MOS Social Support Survey - Emotional/Informational Support, MOS Social Support Survey - Tangible support, Comorbidity Questionnaire, Comorbidity Questionnaire1, Medications/Sexual Function, Weight
E2906 Abbreviated Comprehensive Geriatric Assessment Battery NCT01041703 Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=7586A704-3044-A522-E040-BB89AD4359F8

Input Data Elements CDSS Fall Prevention: Optimize Psychotropic Medication for Geriatric Patients Peterson 2005 - Input Data Elements CDSS Fall Prevention Peterson 2005

- 10/6/16 - 1 form, 1 itemgroup, 4 items, 1 language
Itemgroup: Eligibility criteria
Input Data Elements CDSS to Evaluate the performance of an CDSS for guided prescription of psychotropic medications for geriatric inpatients, published by Peterson et al. 2005

Eligibility Heart Failure NCT02148679

- 5/28/20 - 1 form, 2 itemgroups, 15 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Geriatric Out of Hospital Randomized Meal Trial in Heart Failure; ODM derived from: https://clinicaltrials.gov/show/NCT02148679

DELCODE: DZNE – Longitudinal Cognitive Impairment and Dementia Study - Geriatric Depression Scale (GDS), Geriatric Anxiety Inventory – Short Form (GAI‐SF) (Geriatrische Depressionsskala (GDS) und GAI-SF)

- 4/14/20 - 1 form, 3 itemgroups, 21 items, 1 language
Itemgroups: Administrative Data, Geriatric Depression Scale (GDS), Geriatric Anxiety Inventory – Short Form (GAI‐SF)
DELCODE is conducted by DZNE, the German Center for Neurodegenerative Diseases within the Helmholtz Association. The following information was taken from https://www.dzne.de/en/research/studies/clinical-studies/delcode/. Background and aims: One of the important aims of research into Alzheimer's is to find ways of detecting the disease early – if at all possible, as soon as the first minor symptoms appear, or even before any symptoms at all have appeared. Such detection capabilities are the necessary basis for development of therapies that can be applied at such early stages in the disease. Recent research indicates that such therapies could be more effective than therapies initiated during the disease's later stages. Over a period of several years, the DELCODE study is studying persons in early stages of the disease, along with various risk groups. The research is aimed at the development of procedures for characterizing early stages of the disease, at improving prediction of the course of the disease and at identifying new markers for early diagnosis of Alzheimer's-related dementia. Overview: DELCODE is set up to run for an initial period of three years, and to include a total of 1,000 study participants, who will be examined on a yearly basis. The group of participants will include persons with no complaints (healthy control subjects), patients with slight memory impairment or mild dementia and first-degree relatives of patients with diagnosed Alzheimer's disease. The minimum age for participants is 60. Course of the study: The examinations in the framework of the study will include a comprehensive interview carried out by a study investigator, a detailed neuropsychological examination (testing of memory functions and other areas of cognitive performance), a blood test and a cranial MRI scan. Optionally, subject to the study participant's consent in each case, a lumbar puncture (collection of cerebrospinal fluid) will be carried out." For more information (e.g. principle investigator and study coordination), please visit the above link or https://www.dzne.de. This document contains the Geriatric Depression Scale (GDS) and the Geriatric Anxiety Inventory – Short Form (GAI‐SF). It has to be filled in for Baseline and for all Follow-ups. For use of the questionnaire GDS no licence is required. For more information to the GDS see Yesavage JA, Brink TL, Rose TL, Lum O, Huang V, Adey M, Leirer VO. Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res. 1982-83;17(1):37-49. Due to potential copyright on the questionnaire GAI-SF included in the DZNE DELCODE protocol, GAI-SF will only be included as text result item in this version of the DELCODE forms (at least until permission to publish is received from the original authors or becomes clear upon further research). The respective score items will have a comment in their descriptions about this to distinguish them from score items that were already defined like that by DZNE. For more information to GAI-SF see: Pachana, N., Byrne, G., Siddle, H., Koloski, N., Harley, E., & Arnold, E. (2007). Development and validation of the Geriatric Anxiety Inventory. International Psychogeriatrics, 19, 103-114. doi: 10.1017/S1041610206003504. Rozzini, L., Chilovi, B., Peli, M., Conti, M., Rozzini, R., Trabucchi, M., Padovani, A. (2009). Anxiety symptoms in mild cognitive impairment. International Journal of Geriatric Psychiatry, 24, 300-305. doi: 10.1002/gps.2106.

Safety, Pharmacokinetics and Pharmacodynamics of Refanezumab in Patients with Stroke, NCT00833989 - GDS, MOCA

- 10/4/19 - 1 form, 3 itemgroups, 5 items, 1 language
Itemgroups: Administrative Data, Geriatric Depression Scale, Montreal Cognitive Assessment
Study ID: 111539 Clinical Study ID: 111539 Study Title: A Single-Blind Study of the Safety, Pharmacokinetics and Pharmacodynamics of scalating Repeat Doses of GSK249320 in Patients With Stroke Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00833989 https://clinicaltrials.gov/ct2/show/NCT00833989 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Refanezumab, Placebo Trade Name: N/A Study Indication: Ischaemic Attack, Transient The study consists of 8 visits: Day 1, Week 1 (Day 5), Week 2 (Day 10), Week 4 (Day 30), Week 8 (Day 60), Week 12 (Day 90), Week 16 (Day 112), Follow-up (F/U). All subjects will receive two doses. The first dose within 24-72 hrs after stroke the second dose 9 +/- 1 days after the first one. Each dose will be given as an intravenous infusion over 60 minutes. This document contains the Geriatric Depression Scale (GDS), Montreal Cognitive Assessment (MOCA) Form. It has to be filled in for Week 1, Week 12 and in case of early withdrawal. It also can be filled in unscheduled.

Eligibility Major Depressive Disorder NCT02460666

- 5/6/19 - 1 form, 2 itemgroups, 13 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Brain Connectivity and Response to Tai Chi in Geriatric Depression; ODM derived from: https://clinicaltrials.gov/show/NCT02460666

Eligibility Frailty NCT00718432

- 3/22/18 - 1 form, 2 itemgroups, 14 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
An Interventional Study of Geriatric Frailty, Osteoporosis, and Depression; ODM derived from: https://clinicaltrials.gov/show/NCT00718432

Eligibility Depression NCT00754936

- 7/21/17 - 1 form, 2 itemgroups, 16 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Treatment Response of Geriatric Depression; ODM derived from: https://clinicaltrials.gov/show/NCT00754936

Eligibility Breast Cancer NCT00478283

- 1/16/17 - 1 form, 1 itemgroup, 13 items, 1 language
Itemgroup: Criteria
Views and Attitudes of Oncologists and Geriatricians on the Use of Chemotherapy and Hormone Therapy in Treating Older and/or Frail Women With Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00478283

Eligibility Schizophrenia NCT00085748

- 12/15/16 - 1 form, 2 itemgroups, 10 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Safety Study With Paliperidone ER Extended-Release (ER) Tablets in Geriatric Patients With Schizophrenia; ODM derived from: https://clinicaltrials.gov/show/NCT00085748

Eligibility Intellectual Frailty of Aging NCT02224222

- 1/3/19 - 1 form, 2 itemgroups, 9 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Assessment of Frailty as a Risk Factor for Cardiac and Vascular Surgery; ODM derived from: https://clinicaltrials.gov/show/NCT02224222

Input Data Elements CDSS Prevention of Delirium: With Cognitively Impaired Patients Khan 2013

- 10/12/16 - 1 form, 1 itemgroup, 20 items, 1 language
Itemgroup: Risk factors
Input Data Elements CDSS for Prevention of Delirium: With Cognitively Impaired Patients to evaluate the efficacy of a computer-based clinical decision support system to reduce incidence of delirium in cognitively impaired older adults in the ICU. Published by Khan et al. 2013

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial